Clinical Trial Update: A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating E2609 and its metabolites in subjects with mild and moderate hepatic impairment compared with healthy subjects; study c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• E2609

Snippet

Sponsor: Eisai Inc. | Conditions: Early Alzheimer's Disease | Phase 1 | Status: COMPLETED